S&P 500   3,957.51 (+0.22%)
DOW   32,157.94 (+0.16%)
QQQ   309.60 (-0.05%)
AAPL   159.56 (+0.40%)
MSFT   278.47 (+0.29%)
META   205.07 (+0.39%)
GOOGL   105.04 (-0.53%)
AMZN   97.86 (-0.86%)
TSLA   190.00 (-1.15%)
NVDA   265.76 (-2.26%)
NIO   9.00 (-2.91%)
BABA   86.50 (-0.02%)
AMD   97.57 (-2.70%)
T   18.55 (+0.49%)
F   11.48 (+0.53%)
MU   60.75 (-0.96%)
CGC   1.91 (+0.15%)
GE   90.84 (-0.82%)
DIS   93.88 (-2.03%)
AMC   4.49 (+0.45%)
PFE   40.36 (+0.45%)
PYPL   73.52 (+1.32%)
NFLX   326.67 (+1.97%)
S&P 500   3,957.51 (+0.22%)
DOW   32,157.94 (+0.16%)
QQQ   309.60 (-0.05%)
AAPL   159.56 (+0.40%)
MSFT   278.47 (+0.29%)
META   205.07 (+0.39%)
GOOGL   105.04 (-0.53%)
AMZN   97.86 (-0.86%)
TSLA   190.00 (-1.15%)
NVDA   265.76 (-2.26%)
NIO   9.00 (-2.91%)
BABA   86.50 (-0.02%)
AMD   97.57 (-2.70%)
T   18.55 (+0.49%)
F   11.48 (+0.53%)
MU   60.75 (-0.96%)
CGC   1.91 (+0.15%)
GE   90.84 (-0.82%)
DIS   93.88 (-2.03%)
AMC   4.49 (+0.45%)
PFE   40.36 (+0.45%)
PYPL   73.52 (+1.32%)
NFLX   326.67 (+1.97%)
S&P 500   3,957.51 (+0.22%)
DOW   32,157.94 (+0.16%)
QQQ   309.60 (-0.05%)
AAPL   159.56 (+0.40%)
MSFT   278.47 (+0.29%)
META   205.07 (+0.39%)
GOOGL   105.04 (-0.53%)
AMZN   97.86 (-0.86%)
TSLA   190.00 (-1.15%)
NVDA   265.76 (-2.26%)
NIO   9.00 (-2.91%)
BABA   86.50 (-0.02%)
AMD   97.57 (-2.70%)
T   18.55 (+0.49%)
F   11.48 (+0.53%)
MU   60.75 (-0.96%)
CGC   1.91 (+0.15%)
GE   90.84 (-0.82%)
DIS   93.88 (-2.03%)
AMC   4.49 (+0.45%)
PFE   40.36 (+0.45%)
PYPL   73.52 (+1.32%)
NFLX   326.67 (+1.97%)
S&P 500   3,957.51 (+0.22%)
DOW   32,157.94 (+0.16%)
QQQ   309.60 (-0.05%)
AAPL   159.56 (+0.40%)
MSFT   278.47 (+0.29%)
META   205.07 (+0.39%)
GOOGL   105.04 (-0.53%)
AMZN   97.86 (-0.86%)
TSLA   190.00 (-1.15%)
NVDA   265.76 (-2.26%)
NIO   9.00 (-2.91%)
BABA   86.50 (-0.02%)
AMD   97.57 (-2.70%)
T   18.55 (+0.49%)
F   11.48 (+0.53%)
MU   60.75 (-0.96%)
CGC   1.91 (+0.15%)
GE   90.84 (-0.82%)
DIS   93.88 (-2.03%)
AMC   4.49 (+0.45%)
PFE   40.36 (+0.45%)
PYPL   73.52 (+1.32%)
NFLX   326.67 (+1.97%)
NASDAQ:SRTS

Sensus Healthcare - SRTS Stock Forecast, Price & News

$5.00
+0.04 (+0.81%)
(As of 03/24/2023 02:20 PM ET)
Add
Compare
Today's Range
$4.80
$5.04
50-Day Range
$4.96
$9.49
52-Week Range
$4.80
$15.25
Volume
101,401 shs
Average Volume
234,962 shs
Market Capitalization
$83.05 million
P/E Ratio
3.42
Dividend Yield
N/A
Price Target
$16.83

Sensus Healthcare MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
235.3% Upside
$16.83 Price Target
Short Interest
Healthy
5.21% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars

Medical Sector

293rd out of 989 stocks

Surgical & Medical Instruments Industry

28th out of 99 stocks


SRTS stock logo

About Sensus Healthcare (NASDAQ:SRTS) Stock

Sensus Healthcare, Inc. operates as a medical device company, which provides treatments for both oncological and non-oncological skin conditions. The firm's portfolio of treatment devices includes the SRT-100, SRT-100+, and SRT-100 Vision. Its main product superficial radiation therapy (SRT), a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating basal cell and squamous cell skin cancers, and other skin conditions, such as keloids. The company was founded by Joseph C. Sardano, Richard Golin, Kalman Fishman, and Stephen Cohen on May 7, 2010 and is headquartered in Boca Raton, FL.

Receive SRTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sensus Healthcare and its competitors with MarketBeat's FREE daily newsletter.

SRTS Stock News Headlines

BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Sensus Healthcare drops 21% after Q4 miss
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
Sensus Healthcare, Inc. (SRTS)
Here Are 2 Stocks I'm Focused on Right Now
Short Volatility Alert: Sensus Healthcare, Inc.
See More Headlines
Receive SRTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sensus Healthcare and its competitors with MarketBeat's FREE daily newsletter.

SRTS Company Calendar

Last Earnings
2/09/2023
Today
3/24/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SRTS
Employees
37
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.83
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$14.50
Forecasted Upside/Downside
+236.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$24.24 million
Pretax Margin
65.01%

Debt

Sales & Book Value

Annual Sales
$44.53 million
Cash Flow
$0.27 per share
Book Value
$1.57 per share

Miscellaneous

Free Float
13,894,000
Market Cap
$83.22 million
Optionable
Not Optionable
Beta
0.67

Key Executives

  • Joseph C. SardanoJoseph C. Sardano
    Chairman & Chief Executive Officer
  • Michael J. Sardano
    President, Secretary & General Counsel
  • Magdalena Martinez
    Chief Operating Officer
  • Javier Rampolla
    Chief Financial Officer
  • Russ Price
    Director-Engineering













SRTS Stock - Frequently Asked Questions

Should I buy or sell Sensus Healthcare stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sensus Healthcare in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SRTS shares.
View SRTS analyst ratings
or view top-rated stocks.

What is Sensus Healthcare's stock price forecast for 2023?

3 Wall Street analysts have issued twelve-month price objectives for Sensus Healthcare's shares. Their SRTS share price forecasts range from $14.50 to $20.00. On average, they expect the company's stock price to reach $16.83 in the next year. This suggests a possible upside of 236.0% from the stock's current price.
View analysts price targets for SRTS
or view top-rated stocks among Wall Street analysts.

How have SRTS shares performed in 2023?

Sensus Healthcare's stock was trading at $7.42 at the beginning of 2023. Since then, SRTS stock has decreased by 32.5% and is now trading at $5.01.
View the best growth stocks for 2023 here
.

When is Sensus Healthcare's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our SRTS earnings forecast
.

How were Sensus Healthcare's earnings last quarter?

Sensus Healthcare, Inc. (NASDAQ:SRTS) issued its quarterly earnings data on Thursday, February, 9th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.26 by $0.09. The firm had revenue of $13.11 million for the quarter, compared to analyst estimates of $13.25 million. Sensus Healthcare had a net margin of 54.44% and a trailing twelve-month return on equity of 25.55%.

What ETF holds Sensus Healthcare's stock ?

First Trust Dow Jones Select Microcap Index Fund holds 31,433 shares of SRTS stock, representing 0.13% of its portfolio.

What guidance has Sensus Healthcare issued on next quarter's earnings?

Sensus Healthcare issued an update on its fourth quarter 2022 earnings guidance on Thursday, January, 5th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $13.00M-, compared to the consensus revenue estimate of $12.25 million.

What other stocks do shareholders of Sensus Healthcare own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sensus Healthcare investors own include Ring Energy (REI), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Nabriva Therapeutics (NBRV), Sangamo Therapeutics (SGMO), Viking Therapeutics (VKTX), Vaxart (VXRT), Amarin (AMRN), Palatin Technologies (PTN) and QUALCOMM (QCOM).

When did Sensus Healthcare IPO?

(SRTS) raised $20 million in an IPO on Wednesday, March 30th 2016. The company issued 1,800,000 shares at $10.00-$12.00 per share. Joseph Gunnar and Feltl and Company acted as the underwriters for the IPO and Neidiger, Tucker, Bruner was co-manager.

What is Sensus Healthcare's stock symbol?

Sensus Healthcare trades on the NASDAQ under the ticker symbol "SRTS."

Who are Sensus Healthcare's major shareholders?

Sensus Healthcare's stock is owned by many different institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (1.08%), Empirical Financial Services LLC d.b.a. Empirical Wealth Management (0.90%), G2 Investment Partners Management LLC (0.89%), Navellier & Associates Inc. (0.75%), DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main (0.43%) and DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main (0.43%). Insiders that own company stock include Javier Rampolla, Joseph C Sardano, Michael Sardano, Nicolas Soro, Samuel O'rear, Stephen Brad Cohen and William H Mccall.
View institutional ownership trends
.

How do I buy shares of Sensus Healthcare?

Shares of SRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sensus Healthcare's stock price today?

One share of SRTS stock can currently be purchased for approximately $5.01.

How much money does Sensus Healthcare make?

Sensus Healthcare (NASDAQ:SRTS) has a market capitalization of $83.22 million and generates $44.53 million in revenue each year. The company earns $24.24 million in net income (profit) each year or $1.46 on an earnings per share basis.

How can I contact Sensus Healthcare?

Sensus Healthcare's mailing address is 851 BROKEN SOUND PARKWAY NW SUITE 215, BOCA RATON FL, 33487. The official website for the company is www.sensushealthcare.com. The company can be reached via phone at (561) 922-5808, via email at kgolodetz@lhai.com, or via fax at 561-948-2071.

This page (NASDAQ:SRTS) was last updated on 3/24/2023 by MarketBeat.com Staff